Latest Insider Transactions at Adicet Bio, Inc. (ACET)
This section provides a real-time view of insider transactions for Adicet Bio, Inc. (ACET). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adicet Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adicet Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 05
2024
|
Michael Kauffman |
SELL
Open market or private sale
|
Direct |
5,900
-50.0%
|
$5,900
$1.43 P/Share
|
|
Jun 05
2024
|
Michael Kauffman |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Steve Dubin |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+25.99%
|
-
|
|
Jun 05
2024
|
Aya Jakobovits |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Jeffrey Chodakewitz |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Carl L Gordon |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Andrew Sinclair |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jan 25
2024
|
Carl L Gordon |
BUY
Open market or private purchase
|
Indirect |
3,125,000
+28.21%
|
$6,250,000
$2.4 P/Share
|
|
Jan 25
2024
|
Orbimed Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
3,125,000
+28.21%
|
$6,250,000
$2.4 P/Share
|
|
Jan 24
2024
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,700
+23.96%
|
-
|
|
Jan 24
2024
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,565
-7.69%
|
$7,130
$2.4 P/Share
|
|
Jan 24
2024
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,300
+20.53%
|
-
|
|
Jan 24
2024
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,957
-6.16%
|
$9,914
$2.4 P/Share
|
|
Jan 24
2024
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
70,300
+25.19%
|
-
|
|
Jan 24
2024
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,290
-9.94%
|
$30,580
$2.4 P/Share
|
|
Jan 24
2024
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,300
+20.86%
|
-
|
|
Jan 24
2024
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,320
-5.55%
|
$8,640
$2.4 P/Share
|
|
Jan 24
2024
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,700
+21.41%
|
-
|
|
Jan 24
2024
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,870
-8.47%
|
$9,740
$2.4 P/Share
|
|
Oct 12
2023
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,933
-14.61%
|
$7,933
$1.35 P/Share
|
|
Oct 02
2023
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,093
-9.14%
|
$8,093
$1.37 P/Share
|
|
Oct 02
2023
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,096
-8.36%
|
$7,096
$1.37 P/Share
|
|
Oct 02
2023
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,069
-13.62%
|
$9,069
$1.37 P/Share
|
|
Oct 02
2023
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,208
-13.11%
|
$23,208
$1.37 P/Share
|
|
Oct 02
2023
|
Chen Schor President & CEO |
BUY
Open market or private purchase
|
Indirect |
5,500
+11.23%
|
$5,500
$1.33 P/Share
|
|
Sep 29
2023
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Direct |
5,500
-3.01%
|
$5,500
$1.36 P/Share
|
|
Sep 28
2023
|
Chen Schor President & CEO |
BUY
Open market or private purchase
|
Direct |
5,500
+2.93%
|
$5,500
$1.42 P/Share
|
|
Sep 28
2023
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
5,500
-12.65%
|
$5,500
$1.42 P/Share
|
|
Jun 30
2023
|
Steve Dubin |
BUY
Open market or private purchase
|
Direct |
5,000
+31.45%
|
$10,000
$2.4 P/Share
|
|
Jun 27
2023
|
Carl L Gordon |
BUY
Open market or private purchase
|
Indirect |
875,000
+13.28%
|
$1,750,000
$2.09 P/Share
|
|
Jun 27
2023
|
Orbimed Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
875,000
+13.28%
|
$1,750,000
$2.09 P/Share
|
|
Jun 01
2023
|
Jeffrey Chodakewitz |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jun 01
2023
|
Andrew Sinclair |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jun 01
2023
|
Steve Dubin |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jun 01
2023
|
Carl L Gordon |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jun 01
2023
|
Aya Jakobovits |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jun 01
2023
|
Michael Kauffman |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jun 01
2023
|
Bastiano Sanna Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Feb 15
2023
|
Don Healey Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
4,533
-6.38%
|
$31,731
$7.57 P/Share
|
|
Feb 10
2023
|
Don Healey Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
10,467
-12.83%
|
$73,269
$7.98 P/Share
|
|
Jan 24
2023
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
85,500
+32.58%
|
-
|
|
Jan 24
2023
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,100
+32.46%
|
-
|
|
Jan 24
2023
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,100
+24.24%
|
-
|
|
Jan 24
2023
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,100
+23.51%
|
-
|
|
Jan 24
2023
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,100
+22.76%
|
-
|
|
Nov 10
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-35.96%
|
$600,000
$20.06 P/Share
|
|
Nov 10
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Direct |
9,955
-9.82%
|
$209,055
$21.03 P/Share
|
|
Nov 10
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,967
-19.81%
|
$146,307
$21.0 P/Share
|
|
Nov 07
2022
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-26.45%
|
$570,000
$19.05 P/Share
|